KR100386316B1 - Beverage composition for inhibiting gastric mucosal damage, containing fermented liquid of rice bran and defatted soybean - Google Patents
Beverage composition for inhibiting gastric mucosal damage, containing fermented liquid of rice bran and defatted soybean Download PDFInfo
- Publication number
- KR100386316B1 KR100386316B1 KR1019960030501A KR19960030501A KR100386316B1 KR 100386316 B1 KR100386316 B1 KR 100386316B1 KR 1019960030501 A KR1019960030501 A KR 1019960030501A KR 19960030501 A KR19960030501 A KR 19960030501A KR 100386316 B1 KR100386316 B1 KR 100386316B1
- Authority
- KR
- South Korea
- Prior art keywords
- rice bran
- beverage composition
- defatted soybean
- gastric mucosal
- alcohol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 244000068988 Glycine max Species 0.000 title claims abstract description 23
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 23
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 23
- 235000009566 rice Nutrition 0.000 title claims abstract description 23
- 230000006378 damage Effects 0.000 title claims abstract description 21
- 235000013361 beverage Nutrition 0.000 title claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
- 240000007594 Oryza sativa Species 0.000 title claims abstract 8
- 230000002496 gastric effect Effects 0.000 title abstract description 20
- 239000007788 liquid Substances 0.000 title abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 6
- 235000000346 sugar Nutrition 0.000 claims abstract description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 3
- 229930091371 Fructose Natural products 0.000 claims abstract description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 3
- 239000005715 Fructose Substances 0.000 claims abstract description 3
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 3
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 3
- 229960004853 betadex Drugs 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims abstract description 3
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 3
- 229940094952 green tea extract Drugs 0.000 claims abstract description 3
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 3
- 239000011718 vitamin C Substances 0.000 claims abstract description 3
- 238000000855 fermentation Methods 0.000 claims description 21
- 230000004151 fermentation Effects 0.000 claims description 21
- 210000001156 gastric mucosa Anatomy 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 206010006326 Breath odour Diseases 0.000 abstract description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 235000015165 citric acid Nutrition 0.000 abstract description 2
- 238000004332 deodorization Methods 0.000 abstract description 2
- 238000002845 discoloration Methods 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 239000004310 lactic acid Substances 0.000 abstract description 2
- 235000014655 lactic acid Nutrition 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 244000063299 Bacillus subtilis Species 0.000 abstract 1
- 235000014469 Bacillus subtilis Nutrition 0.000 abstract 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 1
- 229930003471 Vitamin B2 Natural products 0.000 abstract 1
- 229960004106 citric acid Drugs 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 229960002477 riboflavin Drugs 0.000 abstract 1
- 235000019164 vitamin B2 Nutrition 0.000 abstract 1
- 239000011716 vitamin B2 Substances 0.000 abstract 1
- 241000209094 Oryza Species 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 230000035622 drinking Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 239000003777 experimental drug Substances 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- -1 hydrogen ions Chemical class 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
본 발명은 위점막 손상 억제용 음료조성물에 관한 것이다. 더욱 구체적으로, 본 발명은 미강과 탈지대두의 혼합발효액을 함유하여 알코올 섭취후에 나타나는 위점막 손상을 억제하는 음료조성물에 관한 것이다.The present invention relates to a beverage composition for inhibiting gastric mucosa damage. More specifically, the present invention relates to a beverage composition containing a mixed fermentation solution of rice bran and skim soybeans to suppress gastric mucosal damage that occurs after alcohol intake.
[발명이 속하는 기술분야 및 그 분야의 종래기술][Technical field to which the invention belongs and the prior art in that field]
에탄올의 독성에 대해서는 이미 널리 알려져 있음에도 불구하고 현대생활에 있어서 음주의 불가피한 역할은 부인할 수 없다. 일찍이 19 세기 초에 뷰몽(Beaumont)이 에탄올이 인체의 위점막에 발적을 동반한 병리학적 변화를 일으킨다고 보고한 이래 이에 대하여 많은 연구가 이루어져 왔다. 과도한 음주는 인체의 여러 장기에 손상을 초래할 수 있으나 위, 간 및 췌장 등의 소화기관에 손상을 주는 경우가 많고 특히 위점막 손상에 의한 증상을 호소하는 경우를 임상적으로 가장 흔히 경험할 수 있다. 일반적으로 인체에서는 35% 이상의 에탄올 농도에서 현저한 점막 및 점막하 출혈, 괴사, 부종 등이 유발되는 것으로 알려져 있다. 에탄올에 의한 위점막손상 기전은 아직 확실하지 않으나 수소이온에 대한 위점막 방어기전의 손상, 가스트린 분비의 촉진, 위점막혈류 장애, 모세혈관의 투과성 변화, 세포보호기전의 필수적인 요인인 산소유리기 제거기전의 저해 등 다양한 병인들이 제시되고 있으며, 특히 최근에는 산소유리기 제거기전에 많은 관심이 기울여지고 있다. 그러나 이와 같이 알코올이 위점막 손상작용 및 더 나아가서는 위출혈을 야기시키는 작용이 있는 것으로 알려져 있음에도 불구하고, 지금까지 음주후에 복용하는 것으로 알려진 대부분의 약제들은 단순한 소화제이거나 알코올을 분해시켜 제거함으로써 알코올의 혈중농도를 저하시키는 약제, 비타민제, 또는 알코올취를 제거하는 약제 등이 대부분이고, 아직까지 음주후에 복용함으로써 알코올에 의한 급성적인 위점막 손상을 억제하는 효과적인 약제는 개발되지 않았다. 따라서, 음주에 의한 급성적인 위점막 손상을 억제할 수 있는 효과적인 약물의 개발이 요망되고 있다.Although the toxicity of ethanol is well known, the inevitable role of alcohol in modern life is undeniable. Since the early 19th century Beaumont reported that ethanol causes pathological changes with redness in the human gastric mucosa, much research has been done. Excessive drinking can cause damage to various organs of the human body, but it is most often experienced in the gastrointestinal system, such as stomach, liver and pancreas. In general, it is known that significant mucosal and submucosal bleeding, necrosis, and edema are caused at a ethanol concentration of 35% or more in the human body. The mechanisms of gastric mucosal damage caused by ethanol are not yet clear, but impairment of gastric mucosal defense mechanisms against hydrogen ions, promotion of gastrin secretion, gastric mucosal blood flow disorders, changes in capillary permeability, and inhibition of oxygen free radical removal mechanisms, which are essential factors for cytoprotective mechanisms. Various etiologies have been proposed, and in recent years, much attention has been paid to the oxygen free radical removal mechanism. However, although alcohol is known to have effects on gastric mucosal damage and further gastric bleeding, most drugs known to be taken after drinking until now are simply digestive agents or by decomposing and removing alcohol in the blood Drugs that lower concentrations, vitamins, or drugs that remove alcohol odors are mostly used. Thus, no effective drugs have been developed to suppress acute gastric mucosal damage caused by alcohol by taking them after drinking. Therefore, there is a demand for the development of effective drugs that can suppress acute gastric mucosal damage caused by drinking.
이러한 욕구에 따라, 최근들어 알코올에 의한 급성적인 독성을 경감시키는 다양한 종류의 음료조성물들이 앞을 다투어 시판되고 있으나 아직까지 이들 약제들이 실제로 알코올에 의한 위점막 손상을 억제하는 약리학적 효능이 있는 지에 대해서는 밝혀지지 않았다. 이에 본 발명자들은 현재 시판되고 있는 음료조성물중의 하나인 컨디션의 주성분인 미강과 탈지대두의 혼합발효액이 알코올에 의한 위점막 손상에 대한 억제효과가 있는지 여부를 검토하여 보았다.In response to these needs, various types of beverage compositions that alleviate the acute toxicity caused by alcohol have recently been put on the market, but it is still unknown whether these drugs actually have the pharmacological effect of inhibiting gastric mucosal damage caused by alcohol. It is not revealed. Therefore, the present inventors examined whether the mixed fermentation solution of rice bran and skim soybean, which are the main components of the condition, one of the commercially available beverage compositions, has an inhibitory effect on gastric mucosal damage caused by alcohol.
컨디션의 주성분인 미강과 탈지대두의 혼합발효액은 알코올 섭취후의 알코올취 및 구취제거에 효과가 있는 것으로 밝혀져 있으며, 따라서 이에 대하여 이미 특허를 획득한 바 있다(특허 제 84493 호). 그러나 미강과 탈지대두의 혼합발효액이 음주후의 위점막 손상에 대해서도 억제작용을 가지는지에 대해서는 확인된 바가 없었다.The mixed fermentation solution of rice bran and skim soybean, which are the main components of the condition, has been found to be effective in removing alcohol and bad breath after ingesting alcohol, and thus has already obtained a patent (Patent No. 84493). However, it was not confirmed whether the mixed fermentation solution of rice bran and defatted soybean also inhibited gastric mucosal injury after drinking.
따라서, 본 발명자들은 미강가 탈지대두의 혼합발효액이 에탄올에 의한 위점막 손상을 억제할 수 있는지 여부를 알아보기 위하여 다양한 실험을 수행하였으며, 그 결과 미강과 탈지대두의 혼합발효액이 우수한 위점막 손상 억제작용을 나타냄을 확인하고 본 발명을 완성하게 되었다.Therefore, the present inventors conducted various experiments to determine whether the mixed fermentation of rice bran defatted soybeans can inhibit the gastric mucosal damage caused by ethanol, and as a result, the mixed fermentation solution of rice bran and skim soybean showed superior inhibitory effect It was confirmed that the present invention was completed.
따라서, 본 발명은 알코올 섭취후의 위점막 손상을 억제하기 위한 음료조성물에 관한 것이다.Accordingly, the present invention relates to a beverage composition for inhibiting gastric mucosal damage after alcohol consumption.
더욱 구체적으로, 본 발명은 미강과 탈지대두의 혼합발효액을 함유하는, 알코올에 의한 위점막 손상 억제용 음료조성물에 관한 것이다.More specifically, the present invention relates to a beverage composition for inhibiting gastric mucosa damage by alcohol containing a mixed fermentation solution of rice bran and skim soybean.
본 발명의 조성물에서 주성분으로 사용되는 미강과 탈지대두의 혼합발효액은 상기 언급한 특허 제 84493 호(공고번호 제 95-456 호)에 기술된 방법에 의해 미강과 탈지대두를 원료로하여 젖산균과 납두균을 접종하여 발효시켜 제조된 것을 사용한다. 즉, 구체적으로 본 발명의 조성물에서 미강과 탈지대두의 혼합발효액은 미강에 당화효소를 작용시켜 얻은 당화액에 탈지대두를 혼합하여 121℃ 에서 30 분 동안 멸균시킨 후, 젖산균과 납두균을 접종하여 30 내지 40℃, pH 9-9.5 에서 50 내지 100 시간 동안 발효시킨 후, 발효액을 압착여과하여 고형물을 제거하고, 탈색 및 탈취하여 140℃ 에서 4 초 동안 살균하여 얻은 발효액이다.Mixed fermentation broth of rice bran and skim soybean, which is used as a main ingredient in the composition of the present invention, is prepared using rice bran and skim soybean as raw materials by the method described in the above-mentioned Patent No. 84493 (Notice No. 95-456). Inoculate with fermentation to use. Specifically, in the composition of the present invention, the mixed fermentation solution of rice bran and skim soybean is sterilized at 121 ° C. for 30 minutes by mixing skim soybean in the saccharification solution obtained by the action of glycosylation enzyme on rice bran, and then inoculated with lactic acid bacteria and naphtha bacteria 30 Fermentation broth is fermentation broth obtained by fermentation at 40 ° C. and pH 9-9.5 for 50 to 100 hours, followed by compression filtration of the fermentation broth to remove solids, discoloration and deodorization and sterilization at 140 ° C. for 4 seconds.
본 발명의 음료조성물은 목적하는 효과를 얻기 위해서 통상 음주전에, 바람직하게는 알코올을 섭취하기 직전 내지 2 시간 전에 음용함으로써 알코올 섭취후에나타나는 급성 위점막 손상을 억제할 수 있다. 본 발명의 조성물에서 미강과 탈지대두의 혼합발효액은 일반적으로 성인의 음료조성물 총량에 대해 1 내지 10%(v/v), 특히는 3 내지 7%(v/v) 의 비율로 함유되도록 하는 것이 위점막 손상 억제작용의 관점에서 바람직하다.In order to obtain the desired effect, the beverage composition of the present invention can suppress acute gastric mucosal damage that appears after alcohol consumption by drinking before drinking normally, preferably just before ingesting alcohol for 2 hours. In the composition of the present invention, the mixed fermentation solution of rice bran and skim soybean is generally contained in an amount of 1 to 10% (v / v), particularly 3 to 7% (v / v), based on the total amount of the adult beverage composition. It is preferable from the viewpoint of inhibiting gastric mucosal damage.
본 발명의 조성물에는 또한 미강과 탈지대두의 혼합발효액 이외에 추가로 알코올 섭취후의 제증상을 경감시키는 성분들, 예를들면 혈중 알코올 농도 저하용 약제, 비타민제, 당류, 생약 추출물, 또는 약제학적으로 허용되는 첨가제 등이 포함될 수 있다. 이러한 목적으로 첨가되는 성분들의 구체적인 예로는 과당, 설탕, 구연산, 비타민 B2, 비타민 C, 베타사이클로덱스트린, 녹차 추출물, 영지 추출물 등이 언급될 수 있다.In addition to the mixed fermentation broth of rice bran and skim soybean, the composition of the present invention may further reduce the symptoms after ingestion of alcohol, for example, drugs for lowering blood alcohol levels, vitamins, sugars, herbal extracts, or pharmaceutically acceptable ingredients. Additives may be included. Specific examples of ingredients added for this purpose may include fructose, sugar, citric acid, vitamin B 2 , vitamin C, betacyclodextrin, green tea extract, ganoderma lucidum extract.
본 발명은 이하의 실험예에 의해 더욱 구체적으로 설명되나 본 발명이 이들에 의해 어떤 식으로든 제한되는 것은 아니다.The present invention is explained in more detail by the following experimental examples, but the present invention is not limited in any way by these.
실험예 1 : 위점막 손상에 대한 억제효과Experimental Example 1: Inhibitory effect on gastric mucosal injury
본 발명의 조성물의 유효성분인 미강과 탈지대두의 혼합발효액이 알코올 섭취후의 위점막 손상을 억제하는지 여부를 확인하기 위하여 다음과 같은 실험을 수행하였다.In order to determine whether the mixed fermentation solution of rice bran and skim soybean, which is an active ingredient of the present invention, inhibits gastric mucosal damage after ingesting alcohol, the following experiment was performed.
실험동물로는 체중 180g 내지 200g 의 스프라그 도울리(Sprague Dawley)계 자성 백서를 이용하였다. 실험동물을 실험전 24 시간 동안 절대 금식시킨 후, 급식튜브(feeding tube)를 구강을 통해 위내에 삽입하고, 이 튜브를 통해 실험약제를 투여하였다.Sprague Dawley magnetic white paper weighing 180 g to 200 g was used as a test animal. After the animals were absolutely fasted for 24 hours before the experiment, a feeding tube was inserted into the stomach through the oral cavity and the experimental drug was administered through the tube.
실험약제로는 다음 표 1 에 기재된 바와 같은 조성으로 구성된 약제 A 및 B를 사용하였다.As experimental drugs, drugs A and B composed of the compositions as described in Table 1 below were used.
[표 1]TABLE 1
상기 각각의 실험약제인 약제 A 및 B 를 각각 상용량(상기 표 1 에 따라 제조된 양)의 0.33 배, 1 배 및 3 배의 농도로 만든 후 각각의 농도당 5㎖/kg 의 용량으로 위강내 주입하였으며, 대조군에는 생리식염수를 5㎖/kg 의 용량으로 투여하였다. 각 실험군에는 실험동물이 8 마리씩 포함되도록 하였다. 실험동물에게 실험약제 또는 생리식염수를 투여하고 15 분이 경과한 후에 예비실험에서 결정된 양으로 에탄올을 10㎖/kg 의 용량으로 급식튜브를 통해 위강내에 투여하고 1 시간이 경과한 다음 에테르 마취하에 복부를 절개하고 위를 적출하여 대만부를 따라 절개하여 생리식염수로 세척한 다음 위점막 병변을 관찰하며 사진촬영을 하였다. 즉시 위점막을 -70℃ 에 보관하였으며, 이하의 실험에서 병리학적 검사에 사용하였다. 병리학적 검사에 위한 병변부위율의 계산은 계측의 정확도를 기하기 위하여 촬영된 사진을 컴퓨터를 이용한 영상분석 프로그램을 사용하여 크기를 반복 측정하였으며 적출된 위점막 전체 면적에 대한 병변부 면적의 비율로 환산하였다. 측정된 결과는 다음 표 2 에 나타내었다.Each of the experimental drugs, drugs A and B, respectively, was prepared at concentrations of 0.33 times, 1 times, and 3 times the normal dose (amount prepared according to Table 1 above), and then intragastric at a dose of 5 ml / kg for each concentration. The control group was administered with a physiological saline solution at a dose of 5 ml / kg. Each experimental group contained eight experimental animals. 15 minutes after the administration of experimental medicine or saline solution to the experimental animals, ethanol was injected into the gastric cavity through the feeding tube at a dose of 10 ml / kg in the amount determined in the preliminary experiment, and after 1 hour, the abdomen under ether anesthesia. The incision was taken, the stomach was excised, and the incision was made along the Taiwanese section, washed with physiological saline, and then photographed while observing gastric mucosal lesions. Gastric mucosa was immediately stored at −70 ° C. and used for pathological examination in the following experiments. To calculate the accuracy of the lesion site for pathological examination, the size of the lesion was measured repeatedly using a computer-based image analysis program. The ratio of the lesion area to the total area of the gastric mucosa was extracted. In conversion. The measured results are shown in Table 2 below.
[표 2]TABLE 2
궤양 인덱스Ulcer Index
(주) 궤양 인덱스 = 궤양부위의 면적/적출된 위점막의 총면적Ulcer index = ulcer area / total area of extracted gastric mucosa
P : 유의성, 단 B(XO.33) 대 B(X3) 의 유의성은 P<0.05P: Significance, except that B (XO.33) vs. B (X3) is P <0.05
(X 0.33) : 상용량의 0.33 배 용량 투여군(X 0.33): 0.33 times higher dose administration group
(X 1) : 상용량(표 1 에 기재된 양) 투여군(X 1): normal dose (amount shown in Table 1) administration group
(X 3) : 상용량의 3 배 용량 투여군(X 3): three times the dose administration group
상기 표 2 에 기재된 결과로 부터 알 수 있는 바와 같이, 에탄올을 공급하기 전에 실험약제를 투여한 군과 생리식염수만을 투여하였던 군간의 위점막 병변의 발생정도를 비교해 보면, 생리식염수를 투여한 군의 경우에는 궤양 인덱스가 0.0602인데 반하여 상용량의 약제 A 및 B 를 투여한 군에서는 각각 0.0079 및 0.0174 로 생리식염수만을 투여한 경우에 비하여 통계적으로 의미있게 위점막 병변의 발생이 억제되었다. 또한 약제 A 및 약제 B 는 모두 상용량의 0.33 배 및 3 배로 희석 또는 농축하여 투여한 경우에도 각각 생리식염수를 투여한 대조군에 비하여 유의적으로 위점막 병변의 발생을 억제하였으며, 이들의 작용은 약제의 농도에 따라 비례적으로 증가를 나타내었다. 이러한 결과로 부터 미강과 탈지대두의 혼합발효액을 함유하는 본 발명의 조성물은 에탄올에 의한 위점막 병변의 발생에 탁월한 억제효과가 있음을 알 수 있다.As can be seen from the results shown in Table 2, comparing the incidence of gastric mucosal lesions between the group to which the experimental drug was administered and the group to which only saline was administered before ethanol was supplied, In the case of the ulcer index of 0.0602, the upper dose of drugs A and B was 0.0079 and 0.0174, respectively. In addition, drug A and drug B both inhibited the occurrence of gastric mucosal lesions significantly compared to the control group in which saline was administered even when diluted or concentrated to 0.33 times and 3 times the normal dose, respectively. The increase was proportional to the concentration. From these results, it can be seen that the composition of the present invention containing a mixed fermentation solution of rice bran and skim soybean has an excellent inhibitory effect on the occurrence of gastric mucosal lesions caused by ethanol.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019960030501A KR100386316B1 (en) | 1996-07-25 | 1996-07-25 | Beverage composition for inhibiting gastric mucosal damage, containing fermented liquid of rice bran and defatted soybean |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019960030501A KR100386316B1 (en) | 1996-07-25 | 1996-07-25 | Beverage composition for inhibiting gastric mucosal damage, containing fermented liquid of rice bran and defatted soybean |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR980008019A KR980008019A (en) | 1998-04-30 |
| KR100386316B1 true KR100386316B1 (en) | 2003-08-21 |
Family
ID=37417551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960030501A KR100386316B1 (en) | 1996-07-25 | 1996-07-25 | Beverage composition for inhibiting gastric mucosal damage, containing fermented liquid of rice bran and defatted soybean |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100386316B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105341244A (en) * | 2015-10-14 | 2016-02-24 | 哈尔滨工业大学 | Series Clinacanthus nutans tea beverage and preparation method thereof |
| CN105360851A (en) * | 2015-10-14 | 2016-03-02 | 哈尔滨工业大学 | Drooping clinacanthus flavor beverage and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100606553B1 (en) * | 2004-06-22 | 2006-08-01 | 씨제이 주식회사 | Functional Beverage Composition for Improving Ability of Learning, Concentration and Memory |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950000456A (en) * | 1993-06-22 | 1995-01-03 | 가나이 쯔도무 | Power converter |
| KR950010794A (en) * | 1993-10-14 | 1995-05-15 | 김정순 | Hangover beverage composition |
| JPH08149956A (en) * | 1994-09-27 | 1996-06-11 | Nikko:Kk | Fermentation liquid for adding to food or drink, and its production |
| KR100299433B1 (en) * | 1990-03-20 | 2001-11-22 | 기무라 아끼히코 | Preparation of alcohol-resistant fermentation fermentation and alcohol-resistant fermentation food |
-
1996
- 1996-07-25 KR KR1019960030501A patent/KR100386316B1/en not_active IP Right Cessation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100299433B1 (en) * | 1990-03-20 | 2001-11-22 | 기무라 아끼히코 | Preparation of alcohol-resistant fermentation fermentation and alcohol-resistant fermentation food |
| KR950000456A (en) * | 1993-06-22 | 1995-01-03 | 가나이 쯔도무 | Power converter |
| KR950010794A (en) * | 1993-10-14 | 1995-05-15 | 김정순 | Hangover beverage composition |
| JPH08149956A (en) * | 1994-09-27 | 1996-06-11 | Nikko:Kk | Fermentation liquid for adding to food or drink, and its production |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105341244A (en) * | 2015-10-14 | 2016-02-24 | 哈尔滨工业大学 | Series Clinacanthus nutans tea beverage and preparation method thereof |
| CN105360851A (en) * | 2015-10-14 | 2016-03-02 | 哈尔滨工业大学 | Drooping clinacanthus flavor beverage and preparation method thereof |
| CN105360851B (en) * | 2015-10-14 | 2018-04-10 | 哈尔滨工业大学 | Sorrow is escaped grass seasoning drink and preparation method thereof |
| CN105341244B (en) * | 2015-10-14 | 2019-08-23 | 哈尔滨工业大学 | Serial sorrow is escaped careless tea beverage and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR980008019A (en) | 1998-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100372561B1 (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
| US20060068043A1 (en) | Composition for treating chronic venous insufficiencies using an extract of red vine leaves | |
| US20080119567A1 (en) | Methods of use of herbal compositions | |
| KR100686951B1 (en) | A composition having antioxidation effect for preventing or treating impotence | |
| Liu et al. | Cytoprotection by propolis ethanol extract of acute absolute ethanol-induced gastric mucosal lesions | |
| JP3691685B2 (en) | Blood sugar level rise inhibitor | |
| KR100386316B1 (en) | Beverage composition for inhibiting gastric mucosal damage, containing fermented liquid of rice bran and defatted soybean | |
| WO2009076869A1 (en) | Salvianolic acid of high purity, preparation method and use thereof | |
| CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
| KR20140090920A (en) | Pharmaceutical composition and functional food for prevention or treatment of diabetic complications or angioedema comprising natural extract | |
| KR100643877B1 (en) | Pharmaceutical composition for accelerating alcohol metabolism and inhibiting alcoholic liver injury comprising old platycodon extracts as an effective components | |
| KR100592792B1 (en) | Pharmaceutical Composition for Preventing and Treating Hepatitis Comprising Green Tea Catechins as an Active Ingredient | |
| CN103479824B (en) | A kind ofly treat Chinese medicine composition of chronic periodontitis and gastritis and preparation method thereof | |
| EP0813871A1 (en) | Berberine derivates for inhibiting production of HSP47 | |
| JP3393304B2 (en) | Oral preparation for treatment or prevention of hyperlipidemia | |
| CN108261429A (en) | Tuckahoe extract and its active constituent are in the purposes of adjusting, prevention and/or treatment pulmonary lesion | |
| KR100758364B1 (en) | Pharmaceutical composition for preventing or treating impotence | |
| KR100761938B1 (en) | Pharmaceutical composition for preventing or treating impotence induced hyperlipidemia and/or hypertension | |
| KR100902679B1 (en) | Prepartaion of concentrated syrups for oral use containing alcohol fermentated extracts of zingiberis rhizoma and its compounding herbal medicines | |
| JP3605528B2 (en) | Weight gain inhibitor | |
| KR100662206B1 (en) | Pharmaceutical composition for prevention and treatment of gout comprising old red platycodon hydrothermal extracts as an effective components | |
| KR20210109953A (en) | Composition for preventing or treating alcoholic gastritis comprising epigallocatechin gallate and green tea seed extracts | |
| KR20210157343A (en) | Herbal composition for reducing uric acid and the use in reducing uric acid, body fat, and blood glucose thereof | |
| CN109157559A (en) | A kind of drug of the extract containing Chinese mesona herb and its application in prevention and treatment atrophic gastritis | |
| UA154076U (en) | METHOD OF OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COUGH |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20060502 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |